AIP
OBIO icon

Ameritas Investment Partners’s Orchestra BioMed OBIO Stock Holding History

Ameritas Investment Partners’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,396
Closed -$5.97K – 3297
2025
Q1 		$5.97K Hold
1,396
– – ﹤0.01% 2937
2024
Q4 		$5.58K Hold
1,396
– – ﹤0.01% 3014
2024
Q3 		$7.17K Hold
1,396
– – ﹤0.01% 2995
2024
Q2 		$11.4K Hold
1,396
– – ﹤0.01% 2877
2024
Q1 		$7.36K Hold
1,396
– – ﹤0.01% 2892
2023
Q4 		$12.7K Hold
1,396
– – ﹤0.01% 2764
2023
Q3 		$12.2K Buy
1,396
+1,050
+303% +$7.06K ﹤0.01% 2753
2023
Q2 		$2.42K Buy
+346
New +$5.25K ﹤0.01% 3083

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameritas Investment Partners's OBIO Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Orchestra BioMed (OBIO) in Q2 2025, closing a stake of 1,396 shares — an estimated $5.97K sold.

Ameritas Investment Partners first reported a position in OBIO in Q2 2023 and held it in 8 quarters. The position peaked at $12.7K in Q4 2023. 59 funds tracked by Wall St. Rank hold OBIO as of Q2 2025.

  • Ameritas Investment Partners reported no remaining Orchestra BioMed position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 1,396 Orchestra BioMed shares in Q2 2025, an estimated $5.97K.
  • Ameritas Investment Partners first reported a position in Orchestra BioMed in Q2 2023 and held it in 8 quarters.
  • Ameritas Investment Partners's Orchestra BioMed position peaked at $12.7K in Q4 2023.
  • 59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.